Showing 19,861 - 19,880 results of 43,485 for search '(( 5 h decrease ) OR ( 100 ((nn decrease) OR (((mean decrease) OR (a decrease)))) ))', query time: 1.38s Refine Results
  1. 19861

    DataSheet_1_Adenosine receptors differentially mediate enteric glial cell death induced by Clostridioides difficile Toxins A and B.docx by Deiziane V. S. Costa (2627053)

    Published 2023
    “…A2A agonist and A2B antagonist decreased S100B upregulation induced by C. difficile toxins in EGCs. …”
  2. 19862
  3. 19863

    Differential Effects of Type 2 Diabetes Treatment Regimens on Diabetes Distress and Depressive Symptoms in GRADE: A Randomized Clinical Trial by Jeffrey S. Gonzalez (17468874)

    Published 2024
    “…Research Design and Methods: The Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness (GRADE) study of adults with T2DM of < 10 years duration, HbA1c of 6.8-8.5%, and taking metformin monotherapy randomly assigned participants to add insulin glargine U-100, sulfonylurea glimepiride, glucagon-like peptide-1 receptor agonist liraglutide, or dipeptidyl peptidase 4 inhibitor sitagliptin. …”
  4. 19864

    Table_1_Ruminal inocula with distinct fermentation profiles differentially affect the in vitro fermentation pattern of a commercial algal blend.DOCX by Cátia S. C. Mota (18135703)

    Published 2024
    “…Individual ruminal fluids derived from each of the four diets were further used as inocula in in vitro incubations. Here, a 1:1 mixture of corn silage and haylage was supplemented with 0, 5, 10, or 15% algal blend and incubated with each inoculum for 24 h in a 4 × 4 factorial design. …”
  5. 19865

    Diet composition and nutritional values. by Taynara Aparecida Vieira (16401726)

    Published 2025
    “…The HSF group exhibited obesity (HSF 8.77 ± 2.64 <i><i>vs</i></i> C 3.09 ± 1.02, <i>p = </i>0.007), dyslipidemia (HSF 94.4 ± 19.1 <i><i>vs</i></i> C 26.7 ± 5.2, <i><i>p < </i></i>0.001), hypertension (HSF 141 ± 8 <i><i>vs</i></i> C 120 ± 4, <i>p = </i>0.001), insulin resistance (HSF 6.91 ± 1.38 <i><i>vs</i></i> C 2.47 ± 1.01, <i><i>p < </i></i>0.001), cardiac remodeling and dysfunction, cardiac inflammation, decreased metalloproteinase-2 (MMP-2) (HSF 0.43 ± 0.09 <i><i>vs</i></i> C 0.71 ± 0.07, <i>p = </i>0.009) and increased type III collagen (HSF 1.32 ± 0.27 <i><i>vs</i></i> C 1.00 ± 0.18, <i>p = </i>0.038). …”
  6. 19866

    Nutritional and metabolic analysis. by Taynara Aparecida Vieira (16401726)

    Published 2025
    “…The HSF group exhibited obesity (HSF 8.77 ± 2.64 <i><i>vs</i></i> C 3.09 ± 1.02, <i>p = </i>0.007), dyslipidemia (HSF 94.4 ± 19.1 <i><i>vs</i></i> C 26.7 ± 5.2, <i><i>p < </i></i>0.001), hypertension (HSF 141 ± 8 <i><i>vs</i></i> C 120 ± 4, <i>p = </i>0.001), insulin resistance (HSF 6.91 ± 1.38 <i><i>vs</i></i> C 2.47 ± 1.01, <i><i>p < </i></i>0.001), cardiac remodeling and dysfunction, cardiac inflammation, decreased metalloproteinase-2 (MMP-2) (HSF 0.43 ± 0.09 <i><i>vs</i></i> C 0.71 ± 0.07, <i>p = </i>0.009) and increased type III collagen (HSF 1.32 ± 0.27 <i><i>vs</i></i> C 1.00 ± 0.18, <i>p = </i>0.038). …”
  7. 19867

    Cardiovascular parameters. by Taynara Aparecida Vieira (16401726)

    Published 2025
    “…The HSF group exhibited obesity (HSF 8.77 ± 2.64 <i><i>vs</i></i> C 3.09 ± 1.02, <i>p = </i>0.007), dyslipidemia (HSF 94.4 ± 19.1 <i><i>vs</i></i> C 26.7 ± 5.2, <i><i>p < </i></i>0.001), hypertension (HSF 141 ± 8 <i><i>vs</i></i> C 120 ± 4, <i>p = </i>0.001), insulin resistance (HSF 6.91 ± 1.38 <i><i>vs</i></i> C 2.47 ± 1.01, <i><i>p < </i></i>0.001), cardiac remodeling and dysfunction, cardiac inflammation, decreased metalloproteinase-2 (MMP-2) (HSF 0.43 ± 0.09 <i><i>vs</i></i> C 0.71 ± 0.07, <i>p = </i>0.009) and increased type III collagen (HSF 1.32 ± 0.27 <i><i>vs</i></i> C 1.00 ± 0.18, <i>p = </i>0.038). …”
  8. 19868

    Conceptual framework to guide the study. by Resham B. Khatri (10949429)

    Published 2025
    “…Nonetheless, the MMR remains high (151 maternal deaths per 100,000 live births), with a slower rate of decline in recent years, particularly among disadvantaged groups. …”
  9. 19869
  10. 19870
  11. 19871
  12. 19872
  13. 19873
  14. 19874
  15. 19875
  16. 19876
  17. 19877
  18. 19878

    Table 1_Temporal trends and geographic disparities in thyroid cancer burden: a global analysis from 1990 to 2021.doc by Zuzhi Zhao (21724217)

    Published 2025
    “…From 1990 to 2021, the ASPR increased from 14.9 (95% Uncertainty Interval [UI]: 14.1–16.0) to 23.1 (95% UI: 20.7–25.6) per 100,000 population, with an EAPC of 1.58 (95% UI: 1.44–1.73); the ASIR increased from 2.1 (95% UI: 2–2.2) to 2.9 (95% UI: 2.6–3.2) per 100,000 population, with an EAPC of 1.25 (95% UI: 1.14–1.37); the ASDR declined from 0.6 (95% UI: 0.5–0.6) to 0.5 (95% UI: 0.5–0.6) per 100,000 population, with an EAPC of −0.24 (95% UI: −0.24 – −0.21); the age - standardized DALY rate decreased from 15.2 (95% UI: 14.2–16.8) to 14.6 (95% UI: 12.8–16.1) per 100,000 population, with an EAPC of −0.14 (95% UI: −0.17 – –0.11). …”
  19. 19879
  20. 19880

    Table2_Ureteropelvic junction obstruction in infants: Open or minimally invasive surgery? A systematic review and meta-analysis.doc by Valentina Cascini (14162511)

    Published 2022
    “…OP) in infants were included in the meta-analysis. Data (mean ± DS or percentage) were analyzed using Rev.Man 5.4 A p < 0.05 was considered significant.…”